https://www.selleckchem.com/pr....oducts/cl-amidine.ht
Human telomerase reverse transcriptase (TERT) promoter mutations were the most prevalent mutations in patients with hepatocellular carcinoma (HCC). We tried to detect the mutations with plasma circulating tumor DNA (ctDNA) in patients with advanced HCC and elucidated their clinical utility. Circulating tumor DNA in plasma was extracted from 130 patients with advanced HCC who were treated with systemic chemotherapy (n=86) or transcatheter arterial chemoembolization (n=44), and TERT promoter mutations were examined with digital droplet
Like
Comment
Share
